Phase IIB Prostate Combos PARP Enza Chemo
Research payments
$2,308,160
Through program year 2022, $2,308,160 in research payments was reported against Phase IIB Prostate Combos PARP Enza Chemo, across 56 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $27,307 | 2 |
| 2021 | Research | $420,763 | 17 |
| 2020 | Research | $555,464 | 19 |
| 2019 | Research | $1,304,626 | 18 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Daniel Petrylak New Haven, CT Named on 4 payments
- Brendan Curti Portland, OR Named on 4 payments
- Russell Pachynski Saint Louis, MO Named on 3 payments
- Elisabeth Heath Detroit, MI Named on 3 payments
- David Young Rancho Mirage, CA Named on 3 payments
- Manish Agrawal Rockville, MD Named on 2 payments
- Steven McCune Marietta, GA Named on 2 payments
- Ralph Hauke Omaha, NE Named on 2 payments
- Mark Stein New York, NY Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.